Scientific Foundation SPIROSKI, Skopje, Republic of North Macedonia
South East European Journal of Immunology. 2025 Mar 31; 8(CITIM):048
https://doi.org/10.3889/seejim.2025.6110
eISSN: 1857-9388
Category: *CITIM - Cancer Immunotherapy & Immunomonitoring (CITIM2025)*
Section: *Invited Lectures*

Immunotherapy of cancer: are we already there?

Angel Porgador*

The Shraga Segal Dept. of Microbiology, Immunology and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.

Citation: Porgador A. Immunotherapy of cancer: are we already there? SEE J Immunol. 2025 Mar 27;8(CITIM):025. https://doi.org/10.3889/seejim.2025.6110.
Keywords: Cell-based cancer therapy; chimeric antigen receptor (CAR) therapy; modified ERBB receptors' ligands
***Correspondence:** Angel Porgador The Shraga Segal Dept. of Microbiology, Immunology and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
E-mail: angel@bgu.ac.il
Received: 01-Mar-2025
Accepted: 25-Mar-2025
Copyright: © 2025 Angel Porgador. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International
Funding: This research did not receive any financial support
Competing Interests: The authors have declared that no competing interests exist

Abstract

Recent status in cell-based cancer therapy, humoral-based cancer therapy and cancer vaccines will be discussed in short; This will be followed by presentation of data in chimeric antigen receptor (CAR)-therapy employing targeting moieties based on modified ERBB receptors' ligands. The activity and efficacy of modified EGF-like domains derived from NRG1 (ligand to ErbB3 (HER3) receptor) and betacellulin (ligand to ErbB1 (EGFR) receptor) ligands as targeting moiety in CAR therapy will be presented.